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Abstract
Idiosyncratic drug hepatotoxicity represents a major problem in drug development due to
inadequacy of current preclinical screening assays, but recently established rodent models utilizing
bacterial LPS co-administration to induce an inflammatory background have successfully
reproduced idiosyncratic hepatotoxicity signatures for certain drugs. However, the low-throughput
nature of these models renders them problematic for employment as preclinical screening assays.
Here, we present an analogous, but high-throughput, in vitro approach in which drugs are
administered to a variety of cell types (primary human and rat hepatocytes and the human HepG2
cell line) across a landscape of inflammatory contexts containing LPS and cytokines TNF, IFNγ,
IL-1α, and IL-6. Using this assay, we observed drug-cytokine hepatotoxicity synergies for
multiple idiosyncratic hepatotoxicants (ranitidine, trovafloxacin, nefazodone, nimesulide,
clarithromycin, and telithromycin) but not for their corresponding non-toxic control compounds
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(famotidine, levofloxacin, buspirone, and aspirin). A larger compendium of drug-cytokine mix
hepatotoxicity data demonstrated that hepatotoxicity synergies were largely potentiated by TNF,
IL-1α, and LPS within the context of multi-cytokine mixes. Then, we screened 90 drugs for
cytokine synergy in human hepatocytes and found that a significantly larger fraction of the
idiosyncratic hepatotoxicants (19%) synergized with a single cytokine mix than did the non-
hepatotoxic drugs (3%). Finally, we used an information theoretic approach to ascertain especially
informative subsets of cytokine treatments for most highly effective construction of regression
models for drug- and cytokine mix-induced hepatotoxicities across these cell systems. Our results
suggest that this drug-cytokine co-treatment approach could provide a useful preclinical tool for
investigating inflammation-associated idiosyncratic drug hepatotoxicity.
Keywords
drug-induced liver injury; adverse drug reactions; pre-clinical assays; information theory; partial
least-squares modeling
INTRODUCTION
Idiosyncratic drug hepatotoxicity is defined as drug-induced liver injury that occurs in a very
small fraction of human patients, is unrelated to the pharmacologic target of the drug, and is
host dependent (Ganey et al., 2004; Kaplowitz, 2005; Uetrecht, 2007). Idiosyncratic drug
hepatotoxicity is poorly predicted by standard preclinical cell culture and animal models as
well as in clinical trials, and, consequently, most idiosyncratic drug hepatotoxicities are not
evident until after approval for human use. Due to the inability to predict idiosyncratic
hepatotoxicities in the drug development process, idiosyncratic drug hepatotoxicity
frequently leads to drug withdrawal or “black box” warnings and accounts for more than
10% of acute liver failure cases (Uetrecht, 2003; Kaplowitz, 2005). Multiple hypotheses
have been suggested to explain the mechanisms underlying idiosyncratic drug
hepatotoxicity. These include (i) variations in drug metabolism, particularly associated with
alterations in the expression and/or activities of the cytochrome P450 family enzymes, due
to variable environmental conditions and/or genetic polymorphisms in the human population
(Uetrecht, 2008); and (ii) a relationship with concomitant liver inflammation associated with
viral or bacterial infection or liver or inflammatory disease (Ganey et al., 2004). Moreover,
it is likely that multiple factors -- both genetic and environmental -- contribute, at relative
degrees which are not predictable at the present time, to a drug’s hepatotoxicity
idiosyncrasies (Peters, 2005).
A number of preclinical models have been developed in attempts to predict idiosyncratic
drug hepatotoxicity, including the assessment of reactive metabolites through glutathione
(GSH) conjugation assays and the evaluation of animals models by toxicogenomic and
metabolonomic approaches to identify common idiosyncratic hepatotoxicity-associated
biomarkers, with little overall predictive success (Kaplowitz, 2005; Peters, 2005; Obach et
al., 2008). Rodent models administered with bacterial lipopolysaccharide (LPS) have been
recently developed to assess inflammation-associated idiosyncratic drug hepatotoxicity. In
these rodent models, LPS exposure induces a mild inflammatory response that has been
demonstrated to synergistically induce hepatotoxicity in the presence of a number of
idiosyncratic hepatotoxic drugs, including diclonfenac, sulindac, trovafloxacin, ranitidine,
chlorpromazine, but not non- or less-toxic control drugs (Buchweitz et al., 2002; Luyendyk
et al., 2003; Deng et al., 2006; Shaw et al., 2007). In rats, LPS administration upregulates
plasma concentrations of the cytokines tumor necrosis factor-α (TNF), interferon-γ (IFNγ ),
interleukin-1α and -1β (IL-1α/β), interleukin-6 (IL-6), and the chemokine interleukin-10
(IL-10) (Bergheim et al., 2006). Of these, TNF, IFNγ, IL-1α/β, IL-6, and LPS itself all
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stimulate hepatocyte signaling responses through the activation of a diversity of intracellular
signal transduction pathways, including the IKK–NF-κB, p38, and JNK pathways
(associated with TNF, IL-1α/β, and LPS signaling) and the STAT1 and STAT3 pathways
(associated with IFNγ and IL-6 signaling, respectively), which all are implicated in
hepatocellular death in liver diseases and injuries (reviewed in (Luedde and Trautwein,
2006; Schwabe and Brenner, 2006; Malhi and Gores, 2008; Tacke et al., 2008)). In LPS-
administered rat models, synergistic induction of hepatocellular death in the presence of the
idiosyncratic hepatotoxicants ranitidine and trovafloxacin has been reported to be dependent
on TNF signaling (Shaw et al., 2007; Tukov et al., 2007; Shaw et al., 2009). The
observations in LPS-administered rodent models suggest that idiosyncratic drug
hepatotoxicity can arise when mild drug-induced hepatocellular stresses synergize with
LPS-induced inflammatory cytokine signaling to elicit acute hepatocellular death (Ganey et
al., 2004; Kaplowitz, 2005). These stresses may be idiosyncratic in nature in human patients
due variations in drug metabolism, exposure, and/or clearance. The sensitizing role of
hepatocellular stress is supported by the fact that drug-induced depletion of glutathione is
known to sensitize hepatocytes to TNF-induced apoptosis (Mari et al., 2008). Furthermore,
both LPS and inflammatory cytokine signaling can alter hepatocyte expression of
cytochrome P450 enzymes and thus lead to dysregulated drug metabolism and clearance in
conditions of LPS-induced liver inflammation (Warren et al., 1999; Zolfaghari et al., 2007).
Although they offer promise for improved predictability of idiosyncratic hepatotoxicity in
preclinical screening, LPS-administered rodent models lack sufficient throughput for
preclinical screening of candidate pharmaceuticals. Moreover, it has been shown that animal
models are in general not highly predictive of human drug hepatotoxicity, as combined
preclinical testing in rodents, dogs, and monkeys can only identify ~50% of known human
hepatotoxicants (Olson et al., 2000).
Recent advances in the maintenance and characterization of in vitro hepatocyte culture
systems offer substantial promise for their more wide-spread utilization in high-throughput
preclinical screening approaches for theprediction of both non-idiosyncratic and
idiosyncratic drug hepatotoxicity in humans. Amongst hepatocyte culture systems that are
commonly employed for high-throughput preclinical studies, primary human hepatocytes
are considered the “gold standard” for evaluating drug metabolism, transport, and toxicity
(LeCluyse et al., 2005; Hewitt et al., 2007). In comparison, primary rat hepatocytes, while
more readily available and similarly capable of maintaining differentiated hepatic function
in time-scales of a few days in vitro, do not reproduce some aspects of human drug
metabolism (Xu et al., 2004; Sivaraman et al., 2005). Immortalized and transformed human
cell lines (e.g. HepG2 cells) are also frequently employed but have poor maintenance of
liver-specific functions and are relatively insensitive to human hepatotoxicants in simple
cytotoxicity assays (Xu et al., 2004; O’Brien and Haskins, 2007). A small number of
hepatocyte cell culture models have been recently developed to assess idiosyncratic drug
hepatotoxicity. Of note, Xu et al utilized human hepatocyte cell culture models to assay four
sub-lethal hepatotoxicity injuries with high-throughput live-cell microscopy for over 300
drugs, including many that cause idiosyncratic liver toxicity in humans (Xu et al., 2008).
Using a well-calibrated random forest prediction model of the imaging data, they were able
to predict drug hepatotoxicity with a ~50% true-positive rate and ~5% false-positive rate. A
rat hepatocyte-Kupffer cell co-culture model has been developed and shown to successfully
predict chlorpromazine idiosyncratic hepatotoxicity through its synergistic induction of
hepatocellular death following LPS treatment (Tukov et al., 2006). The further development
and validation of hepatocyte cell culture models would provide much-needed tools for the
preclinical evaluation of idiosyncratic drug hepatotoxicity and could offer greater predictive
ability and higher throughput than LPS-administered animal models.
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Here, we describe a model of inflammatory cytokine-associated idiosyncratic drug
hepatotoxicity in three standard hepatocyte cell culture systems amenable to high-
throughput preclinical screening -- primary rat and human hepatocytes and the HepG2
human hepatoblastoma cell line. We initially validate this model to demonstrate that a
number of idiosyncratic hepatotoxic drugs (ranitidine, trovafloxacin, nefazodone,
nimesulide, clarithromycin) synergistically induce hepatocellular death in vitro when co-
administered with a cytokine mix containing the LPS-upregulated cytokines TNF, IFNγ, and
IL-1α, and LPS itself. We then collect a hepatotoxicity data compendium comprised of
combinations of drug and cytokine mix co-treatments covering ~1500 experimental
conditions and analyze it to identify informative cytokine mix treatments and hepatocyte cell
systems for predicting inflammation-associated idiosyncratic drug hepatotoxicity. Using this
data compendium, we show that in vitro drug-cytokine synergies are predominantly
potentiated by TNF, IL-1α, and LPS within the context of multi-cytokine mixes and that
patterns of drug-cytokine mix synergies across a landscape of multi-cytokine environments
can be shown to correlate to drug-induced sub-lethal hepatocyte injury signatures. Then, we
demonstrate the screening utility of this drug-cytokine mix co-treatment model by assaying
a set of 90 drugs in human hepatocytes and show that a significantly larger fraction of
idiosyncratic hepatotoxicants synergize with a single cytokine mix at physiologically
relevant dosing concentrations than do non-toxic drugs. Lastly, we also employ an
information theoretic technique to identify subsets of cytokine co-treatment conditions that
maintain the information contained across the full set of cytokine conditions in the
compendium. We show that these informative condition sets can be transferred across cell
systems and act as better trainings sets for predicting drug- and cytokine-induced
hepatotoxicities in primary human hepatocytes. Our results indicate promise for employing
our approach for efficient in vitro investigation of inflammation-associated idiosyncratic
drug hepatotoxicity.
METHODS
Drugs and cytokines
Most drugs were obtained from Sigma (St. Louis, MO) or Sequoia Research Products
(Pangbourne, UK). Trovafloxacin was obtained from Pfizer’s chemical sample bank
(Groton, CT). Unless otherwise noted, the following drug concentrations were used: 450 μM
ranitidine, 450 μM trovafloxacin, 70 μM nefazodone, 450 μM nimesulide, 175 μM
clarithromycin, and 175 μM telithromycin. These drug concentrations were selected from
initial dosing studies based on the criteria that the drug concentration (i) elicit minimal drug-
only hepatotoxicity, (ii) induce robust supra-additive hepatotoxicity synergy with a
representative cytokine mix, and (iii) be within a physiologically relevant dosing limit of
100-fold its Cmax value, which was satisfied for all drugs except ranitidine, for which a dose
of 317*Cmax was selected (see Figures 1 and S6 for additional details). TPCA-1, an IKK-2
inhibitor, was obtained from Tocris Bioscience (Ellisville, MS). All drugs were suspended in
0.25% final DMSO.
Recombinant rat or human cytokines were obtained from R&D Systems (Minneapolis, MN)
and were used at the following saturating concentrations: 100 ng/ml tumor necrosis factor-α
(TNF), 100 ng/ml interferon-γ (IFNγ), 20 ng/ml interleukin-1α (IL-1α), and 20 ng/ml
interleukin-6 (IL-6). Lipopolysaccharides (LPS) serotype 1 from E. coli 0111:B4 was used
at 10 μg/ml, as previously (Geller et al., 1993). In most cell culture studies, especially
involving monocyte or macrophages (e.g. Kupffer cells), lower LPS concentrations (~1–10
ng/ml) are used (Bellezzo et al., 1996). Though hepatocytes express the LPS receptor TLR4,
they are substantially less responsive to LPS than are macrophages (Geller et al., 1993;
Bellezzo et al., 1996). Consequently, a sufficiently high LPS concentration was selected to
ensure that LPS was fully stimulating hepatocytes and not just the very small fraction of
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Kupffer cells (present at ~0.4% in both human and rat hepatocyte seeding isolates) that may
have remained viable 2–3 days post-seeding. Unless noted, all reagents were obtained from
Sigma.
Drug hepatotoxicity classifications and pharmacokinetic properties
Drug hepatotoxicity classifications were made according to a drug-induced liver injury
(DILI) scale (see Table S1) based on clinical data collected from PubMed searches, as in
(Xu et al., 2008). For select drugs, idiosyncratic hepatotoxicity classifications were assigned
according to literature references (see Table S2). Therapeutically appropriate drug exposure
levels were defined by average plasma maximum concentration (Cmax) values observed in
humans upon single- or multi-dose administration at commonly recommended therapeutic
doses. Cmax values were obtained from a combination of literature searches and available
databases, as in (Xu et al., 2008), and are reported in Table S3. Unless noted otherwise, a
concentration of 100-fold Cmax, encompassing a scaling factor to account for human
population pharmacokinetic and toxicodynamic variabilities, was considered as a
therapeutically relevant dosing limit for each drug, as previously discussed (Xu et al., 2008).
Liver cell isolation, culture, and stimulation
Primary rat hepatocytes were isolated from male Fisher rats using a modified collagenase
perfusion and Percoll isolation, routinely yielding >90% viability, as described previously
(Cosgrove et al., 2008). Cell type purity was assessed by flow cytometry and showed that rat
hepatocyte isolates were routinely comprised of ~97% hepatocytes (albumin+-
cytokeratin-18+ cells), ~0.4% Kupffer cells (ED2/CD163+), ~0.4% stellate cells (GFAP+),
and ~0.2% sinusoidal endothelial cells (SE-1+), as previously reported (Cosgrove et al.,
2008). Rat hepatocytes were seeded on collagen type I-coated 96-well plates (BD
Biosciences, Franklin Lakes, NJ) at 1×105 cells/cm2 in insulin-containing, serum-free
hepatocyte growth medium (HGM; as in (Cosgrove et al., 2008) but supplemented with 1
μM trichostatin A). One day post-seeding, rat hepatocytes were overlayed with 0.25 mg/ml
Matrigel (growth factor-reduced; BD Biosciences) in fresh HGM. One day following
Matrigel overlay, primary rat hepatocytes were stimulated with drugs and/or cytokines in
fresh HGM. For rat and human hepatocyte studies, multiple donors were used throughout
this work, with a single donor used for each self-consistent data set. For rat hepatocytes,
donor-to-donor variability was assessed by comparing two drug- and cytokine mix-induced
hepatotoxicity data compendia (each consisting of the same 256 treatment conditions)
collected from two separate primary rat hepatocyte isolations. The two separate data
compendia showed a high degree of reproducibility (R = 0.98; see Figure S10).
Primary human hepatocytes were obtained in suspension from CellzDirect (Durham, NC).
Cell type purity was assessed by flow cytometry and showed that human hepatocyte isolates
were routinely comprised of ~97% hepatocytes (albumin+-cytokeratin-18+ cells), ~0.4%
Kupffer cells (CD163+), ~0.3% stellate cells (GFAP+), ~0.03% endothelial cells (CD31+),
and 0.03% bile epithelial cells (cytokeratin-19+) (L.G. Alexopoulos, B.D. Cosgrove, and
P.K. Sorger, unpublished results). Human hepatocytes were seeded on collagen type I-
coated 96-well plates at 1.5×105 cells/cm2 in “plating medium” consisting of Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum (FBS;
Hyclone, Logan, UT), 100 U/ml penicillin, 100 μg/ml streptomycin, 0.58 mg/ml L-
glutamine, 1 μM trichostatin A, 0.5 μM dexamethasone, and 5 μg/ml insulin. One day post-
seeding, human hepatocytes were overlayed with 0.25 mg/ml Matrigel in “culturing
medium” consisting of William’s E medium (WEM) supplemented with 15 mM HEPES,
100 U/ml penicillin, 100 μg/ml streptomycin, 0.29 mg/ml L-glutamine, 1 μM trichostatin A,
0.1 μM dexamethasone, 5 μg/ml insulin, 5 μg/ml transferrin, and 5 ng/ml sodium selenite.
One day following Matrigel overlay, human hepatocytes were stimulated with drugs and/or
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cytokines in “dosing medium” (consisting of “culturing medium” but without transferrin and
sodium selenite).
HepG2 cells were obtained from ATCC (Manassas, VA) and were maintained per ATCC
recommendations. HepG2 cells were seeded on collagen type I-coated 96-well plates at
1×105 cells/cm2 in Eagle’s minimum essential medium (EMEM; ATCC) supplemented with
10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. One day after seeding, medium
was changed to fresh EMEM without FBS. One day after medium change, HepG2 cells
were stimulated with drugs and/or cytokines in fresh EMEM without FBS. All cells were
maintained at 37°C and 5% CO2.
Quantitative cell apoptosis and death assays
At 12, 24, or 48 hours post-drug and/or cytokine treatment, conditioned medium samples
were collected to assay lactate dehydrogenase (LDH) release (indicator of necrotic and
apoptotic cell death) and cells were assayed for caspase 3/7 activity (indicator of apoptotic
cell death). LDH activity in culture supernatants was quantified using a CytoTox-ONE
Homogeneous Membrane Integrity Assay (Promega, Madison, WI) according to
manufacturer’s recommendations. Cellular caspase 3/7 activity was quantified using a
Caspase-Glo 3/7 Assay (Promega) according to manufacturer’s recommendations. For each
cell system and time-point, LDH and caspase 3/7 activity assay results were fold-change
normalized to the average DMSO control/no cytokine treatment value from four or more
biological samples from the same 96-well culture plate.
Quantitative sub-lethal hepatotoxicity imaging assays
Drug-induced sub-lethal hepatotoxicity phenotypes were quantitatively imaged in human
hepatocytes in the absence of cytokine co-treatment, essentially as described previously (Xu
et al., 2008). Briefly, human hepatocytes at 24 or 48 hours post-treatment were stained with
four fluorescent probes: DRAQ5 (Biostatus, Shapshed, UK) to stain nuclei and lipids, CM-
H2DCFDA (Invitrogen, Carlsbad, CA) to stain reactive oxygen species (ROS), TMRM
(Invitrogen) to stain mitochondrial membrane potential (MtMP), and mBCl (Invitrogen) to
stain glutathione (GSH). Automated live-cell, multi-color image acquisition was performed
on a Kinetic Scan Reader (Cellomics, Pittsburgh, PA) using a 20× objective and a XP93
filter set (Omega Optical, Brattleboro, VT). Quantitative image analysis was performed
using ImagePro Plus software (Media Cybermetrics, Bethesada, MD). In each image, five
features were quantified: nuclei count and intracellular lipid (non-nuclear DRAQ5 stain),
ROS, MtMP, and GSH contents. For each feature, the summed intensity value from each
well was normalized by the total nuclei count (~500 imaged per well), and then the
intensity-per-cell values were fold-change normalized to the average DMSO control value
from eight or more biological samples from the same 96-well culture plate.
Factorial analysis
The drug-cytokine mix hepatotoxicity compendium was collected such that a full factorial
design of the five cytokine or LPS treatments (25 = 32 mixes) was included for each drug
co-treatment in each cell system. For each drug/cell system, the fold-change normalized
toxicity assay values were subjected to factorial analysis. One-, two-, three-, four-, and five-
factor effects and their associated errors were calculated according to standard factorial
analysis formulae (Box et al., 1978).
Hierarchical clustering
The drug-cytokine mix combinatorial hepatotoxicity compendium was fused across all cell
systems and assay types to generate a hepatotoxicity matrix spanning 192 “experimental”
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conditions (i.e., combinations of cell type, assay readout, and cytokine treatment) and 8 drug
treatments. For each combination of cell system and assay type, the fold-change normalized
values were linearly mapped to a scale from the minimum observed value (set to 0) and the
maximum observed value (set to 1). The fused data compendium was subjected to two-way
clustering using the unweighted pair group method with arithmetic mean and a Pearson
distance metric.
Joint entropy-based representative subset selection
To identify subsets of cytokine treatments that maximally maintain the diversity of
hepatotoxicity responses across different cell systems and assays, a representative subset
selection technique was applied using an information theoretic scoring function. All subsets
considered were constrained to include the no-cytokine treatment as well as all treatments
containing only a single cytokine or LPS. To this set of six conditions, all possible
combinations of other cytokine treatment combinations were added. Each candidate subset
was then scored by computing the joint entropy of all drug hepatotoxicity responses (using
the fold-change normalized data from both the caspase 3/7 and LDH release assays) across
the subset using data from: (i) only primary human hepatocytes, (ii) only primary rat
hepatocytes, (iii) only HepG2 cells, or (iv) both rat hepatocytes and HepG2 cells. Joint
entropies were computed by first discretizing each drug response into three equiprobable
bins and then applying the second-order Maximum Information Spanning Tree
approximation (King and Tidor, 2009). Having scored all cytokine condition subsets, the
maximum-entropy set of each size (i.e. number of cytokine treatment conditions) was
identified. Additionally, a consensus set for each size was selected by including the
conditions that were most prevalent in the top 100 subsets. See Supplementary Methods for
additional details.
Partial least-squares (PLS) regression modeling
To examine the utility of the maximum entropy sets described above, we used them as a
basis for training predictive PLS models of hepatotoxicity across, and within, cell types and
drug treatments. PLS models were built using the PLSREGRESS function in MATLAB
release 2008a (The Mathworks Inc., Natick, MA), which implements the SIMPLS
algorithm. All variables were variance-scaled (with respect to the training set) prior to
learning the model and all models used two principal components. Separate models were
built treating the hepatotoxicity response profile of each drug in human hepatocytes across
the cytokine conditions as the dependent variable. One class of models (“single drug”) was
built in which only the response profiles to the same drug in rat hepatocytes and/or HepG2
cells were used as independent variables. In a second class of models, all drug profiles in rat
hepatocytes and/or HepG2 cells were used. Models were built using the training sets
(containing 25 of the 32 cytokine conditions) and then used to predict the values of the test
sets (containing the remaining 7 conditions), and the correlation coefficient between
predicted and observed values in the test set was computed. For the randomly chosen sets,
all sets were enforced to include the no-cytokine and all five single-cytokine/LPS
conditions, as this constraint was also applied to the maximum entropy consensus sets. See
Supplementary Methods for additional details.
Statistical analysis
To identify drug-cytokine mix co-treatment conditions that elicited supra-additive
hepatotoxicity synergies, additive projections of drug-cytokine mix co-treatments were
estimated by adding mean values of drug-only and cytokine mix-only toxicities and
propagating their associated variances. Supra-additive synergies were identified for
conditions in which the observed drug-cytokine mix co-treatment results exceeded the
additive projections as assessed by a two-sample, one-tailed (Student’s) t test with a false
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discovery rate correction for multiple comparison testing for multiple drug doses or multiple
cytokine mixes. The statistical significance of each factorial effect and its associated error
was assessed using a one-sample, two-tailed t test with a false discovery rate correction for
multiple cytokine mixes. Statistical significance of drug-induced sub-lethal hepatotoxicities
was assessed by a Student’s t test. In the 90-drug study, a threshold two-fold above the
additive projection was used to identify supra-additive drug-cytokine mix synergy due to the
limited number of replicate samples instead of a Student’s t test. The statistical significance
of the observed number of synergistic drugs in the each hepatotoxic group was assessed
using a hypergeometric test (see Table 1 for details). All tests were performed at a
significance level of α = 0.05. False discovery rate-corrected P-values were calculated as: P
= α (N+1)/(2N), where N is the number of comparisons.
RESULTS
Several idiosyncratic hepatotoxic drugs, but not their control-paired compounds, exhibit
drug-cytokine mix hepatotoxicity synergies in vitro
We developed an in vitro model of inflammation-associated idiosyncratic drug
hepatotoxicity by co-administering drug compounds with known idiosyncratic
hepatotoxicities in humans with a variety of inflammatory cytokines mixtures (comprised of
the cytokines TNF, IFNγ, IL-1α, and IL-6, along with LPS) in multiple hepatocellular cell
culture systems (primary human and rat hepatocytes and HepG2 human hepatoblastoma
cells). In developing this model, we investigated drug-cytokine mix hepatotoxicity synergies
for six idiosyncratic hepatotoxic drugs: ranitidine, trovafloxacin, nefazodone, nimesulide,
telithromycin, and clarithromycin (a “comparison” compound for telithromycin also with
idiosyncratic hepatotoxicity). For each drug compound associated with idiosyncratic
hepatotoxicity, a less- or non-hepatotoxic “comparison” control compound was used. In this
study, the term “comparison” compound wasapplied to drugs with similar molecular target
and clinical indication and, where possible, similar chemical structure. See Table S2 for
additional information on these drugs and their corresponding comparison compounds.
Initially, this in vitro drug-cytokine mix co-treatment model was applied to primary rat
hepatocytes and HepG2 cells treated with five pairs of drug compounds in the presence or
absence of a single cytokine mix containing TNF, IFNγ, IL-1α, and LPS and assayed for
LDH release as a marker of both apoptotic and necrotic cell death (Figures 1 and S1-S5).
Synergistic induction of hepatocellular death was assessed by a supra-additive synergy
criterion that compares the experimentally observed cell death induced by drug and cytokine
co-treatment to the additive projection of cell death observed for drug-only and cytokine
mix-only treatments (Figure S6).
In this co-treatment model, we observed drug-cytokine mix synergies for ranitidine but not
cimetidine or famotidine (data not shown) in rat hepatocytes (but not HepG2 cells),
matching similar observations in a LPS-administered rat model (Luyendyk et al., 2003). We
observed drug-cytokine mix synergies for trovafloxacin but not levofloxacin in both rat
hepatocytes and HepG2 cells, again matching similar observation in a LPS-administered
mouse model (Shaw et al., 2007). For drugs not previously examined in LPS-administered
animal models, we observed drug-cytokine mix synergies for nefazodone (but not
buspirone) and clarithromycin in both rat hepatocytes and HepG2 cells, and nimesulide (but
not aspirin) and telithromycin in only HepG2 cells. In this initial study, drug-cytokine mix
synergies were observed only for the more idiosyncratic hepatotoxic drugs, except for
clarithromycin and telithromycin, which both synergized with cytokine mix co-treatment
and both have associated idiosyncratic hepatotoxicity with telithromycin having a greater
incidence (see Table S2 and (Peters, 2005; Clay et al., 2006)). Drug-cytokine mix
hepatotoxicity synergies were observed within 24 hr following co-treatment except for
ranitidine in rat hepatocytes, which required 48 hr of co-treatment to elicit hepatotoxicity
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synergy, demonstrating that, at the drug and cytokine treatment concentrations used, this in
vitro model captures acute, rather than chronic, hepatotoxicity responses. The delay in
ranitidine-cytokine mix synergy compared to other compounds, in concert with the
observation that it only occurs in rat hepatocytes and not HepG2 cells, indicates that a more
prolonged mechanism (e.g. requiring significant accumulation of ranitidine metabolites)
may be required to potentiate ranitidine-cytokine hepatotoxicity synergy.
Specific concentrations and time-points for each drug were selected for further investigation
(see summary in Table S2) based on the criteria that the concentration induce robust supra-
additive hepatotoxicity synergy with this representative cytokine mix (Figure S6) and elicit
minimal drug-only hepatotoxicity. This selection criteria allowed for identification of drug
concentrations within a physiologically relevant dosing limit of 100-fold its Cmax value (see
Methods for additional explanation) for all cytokine-synergizing drugs except ranitidine, for
which a dose of 450 μM or 317*Cmax was used.
Collection and analysis of a combinatorial drug- and cytokine mix-induced hepatotoxicity
compendium from multiple hepatocyte cell systems
To characterize drug-cytokine mix synergies in a more diverse set of cytokine environments
and to make comparisons across hepatocyte cell culture systems, we collected a multi-cue
data compendium from all combinations of six idiosyncratic hepatotoxic drugs from the
initial study -- each at one concentration and time-point -- and a DMSO control, and the 32
combinatorial mixtures of TNF, IFNγ, IL-1α, IL-6, and LPS. (Note that IL-6, not included in
the initial study due to its presumed pro-survival effects (Luedde and Trautwein, 2006), was
included in this combinatorial study.) Experiments were performed in rat hepatocytes,
human hepatocytes, and HepG2 cells and then assayed for both LDH release and caspase 3/7
activity, a marker specific to apoptotic cell death (Figures 2 and S7-S9). The hepatotoxicity
data compendium, comprised of ~1500 combinations of cell system, assay type, and drug-
cytokine treatment, was observed to contain a diverse array of drug-cytokine synergy
patterns not clearly interpretable by inspection alone, so we subjected it to four analytical
approaches. (i) We discretized the hepatotoxicity data compendium into conditions that did
or did not elicit supra-additive drug-cytokine mix synergy (Figure S11). (ii) We subjected
the hepatotoxicity data compendium to factorial analysis to identify which underlying
cytokine treatment factors potentiate cell death across the entire combinatorial landscape of
cytokine environments (Figures S12-S15). (iii) We employed hierarchical clustering of the
hepatotoxicity data compendium with respect to both drug treatments and “experimental”
conditions (i.e., combinations of cell type, assay readout, and cytokine treatment; Figure
3A). (iv) We identified subsets of cytokine conditions that maximally maintained the
information content of the response data (Figure 5).
From the first analysis approach, examining discretized drug-cytokine synergy classification
(Figure S11), it is evident that higher-order (four- or five-factor) cytokine environments
were more efficient at identifying possible drug synergies (~50% of possible synergies
across combination of all cell systems and drugs) than were lower-order (one-, two-, or
three-factor) environments (~15–35% of possible synergies). Of note, there are higher-order
cytokine mixes other than the mix of TNF, IFNγ, IL-1α, and LPS (which was used in the
initial study) that are more efficient at synergizing with these idiosyncratic drugs in human
hepatocytes. This is in part due to the fact that the initial cytokine mix is mildly toxic by
itself for human primary hepatocytes, limiting its ability to synergize with drug co-
treatments in a supra-additive manner. Instead, slightly less-toxic five-factor mixes (in
particular, the five-factor mixes that instead do not contain either TNF or IFNγ [the latter
noted as “2” in Figure S11A]) are far more efficient at eliciting supra-additive hepatotoxicity
synergies with these six idiosyncratic drugs in human hepatocytes, and therefore would
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likely serve as a more predictive cytokine environment for assessing drug-cytokine
synergies in human hepatocytes.
In the second analysis approach, we applied factorial analysis to the hepatotoxicity data
compendium to identify underlying cytokine effects potentiating drug-cytokine
hepatotoxicity synergies across the entire landscape of cytokine environments (Figures S12-
S15). As implemented here, factorial analysis calculates the effect of the addition or removal
of component treatment “variables”, each containing one-to-four cytokines and/or LPS,
from all treatment conditions in which they are present or absent, and, as such, summarizes
the average effect of each cytokine treatment “variable” within the context of all other
cytokine co-treatment conditions (Box et al., 1978). Higher-order factorial effects (those
containing more than two cytokine variables) were generally modest, and, instead, one- and
two-cytokine factorial effects dominated the observed drug- and cytokine mix-induced
hepatotoxicities. The most significant effects, across all cell types and drug co-treatments,
arose from the single-cytokine treatment variables of TNF and, to a lesser extent, IL-1α and
LPS (see Supplemental Methods and Results for additional discussion). The identification
via factorial analysis of TNF as a potentially important cytokine mediator of the
inflammation-associated hepatotoxicity of multiple idiosyncratic drugs is in agreement with
reports that TNF mediates the LPS-induced hepatotoxicity of both ranitidine (Tukov et al.,
2007) and trovafloxacin (Shaw et al., 2007; Shaw et al., 2009).
Clustering of the drug-cytokine mix hepatotoxicity compendium to assess hepatotoxicity
patterns with respect to cell system, assay type, and drug-induced hepatocellular injuries
Factorial analysis of the hepatotoxicity data compendium suggested a significant degree of
variability in cytokine factors potentiating idiosyncratic drug hepatotoxicity synergies in
different drug backgrounds and cell systems. To further assess these differences, we fused
the hepatotoxicity data compendium into a single data matrix of 192 “experimental”
conditions (comprised of all combinations of three cell systems, two assay types, and five
cytokine/LPS treatment variables) by eight “drug” conditions (six idiosyncratic drugs and
two DMSO controls). This hepatotoxicity data matrix was subjected to two-way hierarchical
clustering to assess patterns of drug-cytokine mix synergies across both the 192
experimental conditions and the 8 drug or DMSO backgrounds (Figure 3). Pearson
clustering yielded the most distinct separation with respect to assay readouts due to the fact
that they are poorly correlated (R = 0.18) across the entire data set. A second notable
grouping was that of the different cell types, with large sections of each assay type cluster
consisting solely of the conditions from each cell system, showing that there was little
overlap between the three hepatocyte cell systems. Inspection within the LDH and caspase
data clusters revealed that neither rat hepatocytes nor HepG2 cells were distinctly better
correlated with human hepatocytes in this data compendium.
It has been proposed that a conserved mechanism of inflammation-associated idiosyncratic
toxicity is that sub-lethal hepatocellular injuries induced by idiosyncratic drugs and/or their
metabolites sensitize hepatocytes to undergo cytokine-stimulated cell death (Kaplowitz,
2005). We hypothesized that there might exist correlations between the patterns of drug-
cytokine mix lethal hepatotoxicities and a set of four sub-lethal hepatocyte injury
measurements for the six idiosyncratic drugs in this study. Drug-induced sub-lethal
hepatocyte injuries were measured in human hepatocytes, in the absence of any cytokines,
using a high-throughput live-cell microscopy approach (Xu et al., 2008), which quantifies
lipid content, reactive oxygen species (ROS), mitochondrial membrane potential (MtMP),
and glutathione (GSH) depletion (Figure S16). It was difficult to discern clear correlations
between sub-lethal injuries (measured in human hepatocytes) and cytokine synergy
clustering patterns (across all three hepatocyte systems) for nimesulide, clarithromycin, and
nefazodone due to the numerous sub-lethal hepatotoxicities induced by these drugs (Figure
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3A), and thus synergy correlations possibly reflect the convolution of multiple sub-lethal
injury-cytokine synergy mechanisms. In contrast, the only sub-lethal injury induced by both
telithromycin and trovafloxacin that was statistically significant was MtMP depletion
(Figures 4C and S16). In human hepatocytes, telithromycin and trovafloxacin elicited
markedly similar patterns of cytokine synergy as assayed by caspase 3/7 activity and
represented through factorial analysis (Figure 3B). For both drugs, cytokine synergy effects
were evident, in decreasing magnitude, for LPS and IL-1α but not other treatment variables.
This pattern of cytokine synergy effects was not shared by any other drugs at 24 hours post-
treatment in human hepatocytes (Figure S14). This unique and specific sub-lethal injury-
cytokine synergy relationship suggests that drug-induced mitochondrial injury may sensitize
hepatocytes to apoptosis induced by LPS and IL-1α, as has been similarly hypothesized for
alcoholic hepatitis-induced mitochondrial injury in hepatocytes (Hoek and Pastorino, 2002).
Large-scale screen in primary human hepatocytes demonstrates the utility of cytokine co-
treatment synergy model as a tool for identifying idiosyncratic hepatotoxic drugs
To test the drug-cytokine mix hepatotoxicity synergy model as a screening tool for
identifying inflammation-associated idiosyncratic drug hepatotoxicity, we assayed drug-
cytokine mix synergy for 90 drugs in human hepatocytes. This set of 90 drugs included 53
hepatotoxic drugs from DILI classes P1, O1, and P2 and 36 non-hepatotoxic drugs from
DILI classes O2, N3, N2, and N1 (see Tables S1 and S3 for additional details). DILI class
P2 is substantially comprised of drugs with idiosyncratic hepatotoxicities in humans and
therefore assumed for analysis purposes here and previously (Xu et al., 2008) to represent
idiosyncratic drugs. The non-hepatotoxic group (DILI O2, N3-N1) is used to provide
corresponding non-toxic control compounds, although we note that the idiosyncratic drugs
clarithromycin and ranitidine used in the initial study here are in DILI classes N1 and N3,
respectively. In this 90-drug screen, comparisons were made by examining the differences
between the idiosyncratic group (DILI P2) and the non-hepatotoxic group as not all
idiosyncratic drugs could be individually paired with “comparison” control drugs.
Due to practical limitations in conducting medium-to-high-throughput screens in primary
human hepatocytes, we assessed drug-cytokine mix synergy only for a single cytokine mix
(TNF, IL-1α, IL-6, and LPS), which was equally effective at inducing hepatotoxicity
synergies across the six idiosyncratic drugs as the full set of cytokine mixes in the initial
drug-cytokine mix data compendium (see Figure S11A, mix noted as “2”). Human
hepatocytes were treated with one of 90 drugs, each dosed between 0 and 150 μM, in the
presence or absence of TNF, IL-1α, IL-6, and LPS and assayed for LDH release at 24 hr
post-treatment (Figures 4 and S17). Supra-additive drug-cytokine synergy was assessed with
regards to two different methods of defining a physiologically relevant dosing limit: (i)
using each drug’s own 100*Cmax concentration, or (ii) using multiples (33× or 100×) of the
median Cmax concentration for all drugs in this study (0.91 μM) as an general estimate of
physiological exposure limit, which may be a necessary approximation if clinical human
pharmacokinetic data is unavailable.
For doses less than each drug’s own 100*Cmax concentration, drug-cytokine mix synergy
was observed for the P1 compounds benzbromarone, demeclocycline, azathioprine,
amiodarone, retinoic acid; the O1 compound menadione; the P2 compounds trovafloxacin,
diclofenac, quinine, chlorpromazine, riluzole, mexiletine, clomipramine, nortriptyline; and
the N1 compound clarithromycin (which has reported idiosyncratic hepatotoxicity in
humans (Peters, 2005; Clay et al., 2006) and was used as a test idiosyncratic hepatotoxicant
in the initial study here). Among these cytokine mix synergy compounds, three of the six
overtly hepatotoxic drugs (P1 compounds benzbromarone and azathioprine and the O1
compound menadione) and two of the eight idiosyncratic hepatotoxic drugs (P2 compounds
quinine and chlorpromazine) also induced significant drug-only hepatotoxicity at doses less
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than each drug’s own 100*Cmax concentration (Figure S17 and data not shown). In this data
set, drug-only hepatotoxicity was defined as greater than two-fold increase in LDH release.
Using this approach to physiological concentration limit, a significantly larger fraction of the
idiosyncratic hepatotoxic drugs (8 of 43 = 19%) demonstrated hepatotoxicity synergy with
the cytokine mix than did the non-hepatotoxic drugs (1 of 36 = 3%; see Table 1). In contrast,
using 100-fold the median Cmax concentration (91 μM) as an general estimate of
physiologically relevant dosing limit, the idiosyncratic hepatotoxic drugs (9 of 43 = 21%)
did not elicit more frequent hepatotoxicity synergy then the non-hepatotoxic drugs (7 of 36
= 19%). But in using 33-fold the median Cmax concentration (30 μM), the idiosyncratic
hepatotoxic drugs (7 of 43 = 16%) did elicit more frequent hepatotoxicity synergy then the
non-hepatotoxic drugs (0 of 36 = 0%).
This demonstrates that synergistic induction of hepatotoxicity with a cytokine mix, even
when limited to a single hepatocyte cell system and cytokine mix, can be utilized as a
screening tool for evaluating inflammation-associated idiosyncratic drug hepatotoxicity. As
implemented here, optimized assessment requires knowledge of the drug’s Cmaxvalue,
which necessitates human clinical pharmacokinetic data, but a reduced set of idiosyncrasies
can be reproduced with a more conservative estimate of liver exposure (33*Cmax) based on a
generalized Cmax estimate calculated from many drugs. Moreover, idiosyncratic hepatotoxic
drugs (P2 compounds) largely induce drug-cytokine mix synergies in the absence of drug-
only hepatotoxicities, which are more often evident for synergizing drugs that are associated
with overt hepatotoxicity. This dependency on Cmax to optimally calibrate the drug-cytokine
mix synergy model to distinguish between drugs with idiosyncratic hepatotoxicity and those
with either no or overt hepatotoxicity is in concert with Paracelsus’ concept that “exposure
makes a poison”.
Joint entropy analysis identifies informative cytokine environments in rat hepatocytes and
HepG2 cells for characterizing human hepatocyte drug-cytokine mix death synergies
The poor correlation in drug-cytokine hepatotoxicity patterns between all three hepatocytic
cell types (Figure 3) indicated it would be difficult to make accurate predictions of drug- and
cytokine-induced hepatotoxicities in primary human hepatocytes from primary rat
hepatocyte and/or HepG2 data. To examine this further, we asked whether a subset of the 32
cytokine conditions present in the drug-cytokine mix data compendium could be identified
that maintained the diversity of the hepatotoxicity responses present in the full set of
experiments. Such a subset could prove useful for motivating future experiments in a more
compact experimental scope. To quantify the information content of a set of cytokine co-
treatments, we computed the joint entropy of all drug hepatotoxicity responses across both
assays and in all three cell systems using Maximum Information Spanning Trees, a
framework for approximating high-dimensional information theoretic statistics with limited
sample sizes (King and Tidor, 2009). This joint entropy metric quantifies the diversity of
hepatotoxicity responses across the entire data compendium, accounting for relationships
between drugs, assays, and cell systems. We assessed the information content of all possible
subsets of cytokine co-treatments using the joint entropy metric, and selected the highest
scoring subset of each size (Figure 5A) in the human hepatocyte data set, as well as a
consensus set that considered the 100 most information-rich subsets of each size (data not
shown). This analysis identified subsets containing 16–19 cytokine co-treatments with
comparable information content (91–99%) to the full set of 32. The consensus subsets, while
not as information-rich, also had similar information content to the full set (89–98%).
While the above results suggest that the number of conditions used could be reduced by as
much as half while maintaining much of the information content, the selection scheme relied
upon knowledge of the full data set. While primary human hepatocytes are considered to be
the cell system with most predictive of human hepatotoxicity (Gomez-Lechon et al., 2003;
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LeCluyse et al., 2005), they are also less amenable to high-throughput investigation due to
their higher cost and lower availability. We therefore asked whether a compact subset of
highly informative treatment conditions for human hepatocyte studies could be identified
using only the experimental data from primary rat hepatocytes and HepG2 cells. We
repeated the joint entropy analysis described above using data from (i) only HepG2 cells, (ii)
only rat hepatocytes, or (iii) both rat hepatocytes and HepG2 cells (Figure S18). We then
evaluated the treatment subsets chosen from each data set by their joint entropy in the
human hepatocyte data (Figures 5B-C). While the sets chosen without the human hepatocyte
data were less informative than the optimal sets (e.g. 95% of the total possible entropy for
the optimal 16-treatment set compared to 90% using a 16-treatment set chosen by rat
hepatocyte and HepG2 data), they still performed significantly better than randomly chosen
sets (which averaged 77% of the total possible entropy for 16-treatment sets). Additionally,
the sets chosen using both the rat hepatocytes and HepG2 data generally outperformed sets
chosen using either data set alone, suggesting that both cell systems were separately
informative of the human hepatocyte hepatotoxicity observations. The results demonstrate
that reduced-condition treatment sets can be identified from exhaustive data sets collected in
cell systems more amenable to high-throughput investigations (rat hepatocytes and HepG2
cells) for more focused, but still fully informative, experiments in higher-cost systems
(human hepatocytes).
Maximum entropy sets act as better training sets for partial least squares regression
models of drug- and cytokine-induced toxicity in primary human hepatocytes
To examine the utility of the maximum entropy sets described above, we used them as a
basis for training a predictive model. We took the approach of building statistical regression
models to predict the drug- and cytokine mix-induced hepatotoxicity responses in human
hepatocytes, based upon the analogous measurements in the rat hepatocyte and HepG2 cell
systems. For each drug and hepatotoxicity assay, we built a partial least-squares (PLS)
regression model that predicted the hepatotoxicity responses in human hepatocytes based
upon training data from rat hepatocytes and/or HepG2 cells. We built the models using two
different sets of inputs that reflect different experimental modalities. In one case (“single
drug”), when building a model of the response of a given drug across the various cytokine
backgrounds in human hepatocytes, we used as training data only the response to the same
drug in both other cell systems and both assays. In a second case (“all drugs”), the response
profiles of all drugs were used to predict each individual drug response. To evaluate the
predictive performance of these PLS models, a subset of the cytokine conditions containing
25 cytokine conditions (training set) were used to train the model, and the trained model was
then used to predict the response in the remaining 7 cytokine conditions (test set). These set
sizes showed the best predictive performance as well as the most improvement using
maximum entropy-selected sets compared to random sets (see Figure S19). As a
comparison, we chose 1000 sets of each size at random and trained models from these sets,
with the mean performance across all drug responses reported.
We examined whether the information-rich maximum entropy sets would act as better
training sets when learning the PLS models. All maximum entropy consensus sets had
higher mean correlation between predictions and observed values than the randomly chosen
sets (Figure 6, Table S4). Importantly, the consensus sets identified using the data from
HepG2 cells or both rat hepatocytes and HepG2 cells both lead to PLS models that
performed much better than randomly-selected subsets. Additionally, the models trained
using all of the drug data consistently outperformed the single drug models, suggesting that
parallel drugs studies may prove useful in predicting the behavior of individual drugs. These
modeling results show that, in addition to the identity of information-rich cytokine treatment
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conditions being transferable across cell systems, the subsets themselves can also act as
superior training sets for predicting hepatotoxicity responses in unmeasured conditions.
DISCUSSION
Hepatotoxicity is a major cause of failures in both the clinical and post-approval stages of
drug development and thus represents a major challenge for the pharmaceutical industry
(Kaplowitz, 2001; Lee, 2003). Furthermore, drug hepatotoxicity represents a serious public
health problem, as it is the leading cause of acute liver failure in the United States
(Ostapowicz et al., 2002). Idiosyncratic drug hepatotoxicity -- a hepatotoxicity subset that
occurs in a very small fraction of human patients (~1 in 10,000) and accounts for ~10% of
acute liver failure cases -- is poorly predicted by standard preclinical models and in clinical
trials and frequently leads to post-approval drug failure (Kaplowitz, 2005). Thus, the
development and validation of novel preclinical tools that demonstrate successful
identification of idiosyncratic drug hepatotoxicity is a paramount need for the
pharmaceutical industry and the public health. Recent findings in LPS-administered rodent
models suggest that idiosyncratic drug hepatotoxicity can arise when mild drug-induced
hepatocellular stresses synergize with inflammatory cytokine signaling to elicit
hepatocellular death, but these models lack sufficient throughput for preclinical
hepatotoxicity screening (Ganey et al., 2004; Kaplowitz, 2005).
In this work, we developed and evaluated in vitro hepatocyte cell culture models of
idiosyncratic drug hepatotoxicity, which are more suitable to the high-throughput demands
of preclinical pharmaceutical screening. In our cell culture model, synergistic induction of
hepatocellular death by drugs and inflammatory cytokines is used to reproduce known
idiosyncratic drug hepatotoxicities. The in vitro cytokine synergy model developed herein
and other complementary cell culture (Xu et al., 2008) and animal models (Buchweitz et al.,
2002; Luyendyk et al., 2003; Shaw et al., 2007) offer much-needed preclinical tools for the
assessment and prediction of idiosyncratic drug hepatotoxicity. This cytokine synergy model
would be most useful simply for its ability to identify candidate idiosyncratic hepatotoxicity
phenomenologies. Identification of candidate idiosyncratic hepatotoxicants in cell culture
allows for more detailed follow-up experiments to parse the mechanisms of particular
candidate idiosyncratic hepatotoxicants to help guide drug compound development. We
focused the development of our cell culture model on the simple case of static, simultaneous
drug-cytokine mix co-exposure over an acute time scale (24–48 hr). Cell culture models
more consistent with idiosyncratic drug hepatotoxicity physiology would need to include the
relative dynamics of both drug and cytokine exposure. Clinically, drug exposure can be
quite cyclical (i.e., oscillating between Cmax and Cmin for a repeatedly administered drug at a
pre-defined dosing interval). While cytokine exposure can be static (due to, for example, a
pre-existing inflammatory event), cytokine levels can also be highly cyclical, especially in
the case of hepatotoxicant-induced inflammation (Horn et al., 2000; Ganey et al., 2004).
We demonstrated that numerous idiosyncratic hepatotoxic drugs, but not comparison non-
toxic control compounds, synergistically induce death in multiple hepatocyte cell systems
when co-administered with multi-cytokine mixes associated with LPS-induced liver
inflammation (Figure 1). In primary rat and human hepatocyte cultures in particular, drug-
cytokine mix synergies were most frequently observed for higher-order (containing four or
five cytokines or LPS) cytokine mixes (Figure S11), whose hepatotoxicity was potentiated
in a drug- and cell system-specific manner by the additive combination of the single-factor
effects of TNF, IL-1α, and/or LPS (Figure S12). Our results demonstrate that LPS itself can
amplify drug hepatotoxicity, but this effect is predominantly observed when LPS is co-
administered with other cytokines in the presence of multi-cytokine mixes (Figure S11A).
When LPS was administered in the absence of other cytokines (mirroring in vivo studies
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when LPS is administered upon inhibition or removal of Kupffer cells), it yielded very
infrequent drug synergies. Together, these observations confirm that other cytokines are
necessary for LPS to have an effect in inducing hepatotoxicity in combination with
idiosyncratic hepatotoxicants). This agrees with previous reports (Shaw et al., 2007; Tukov
et al., 2007) that Kupffer cell-mediated cytokine release is necessary for LPS-induced
hepatotoxicity in combination with idiosyncratic hepatotoxicants in animal models.
Potentiation of drug-cytokine synergy by TNF, IL-1α, and LPS, more so than by IFNγ or
IL-6, suggests that signal transduction pathways that are similarly downstream of the
cytokine receptors TNFR and IL-1R and the LPS receptor TLR4 (Liu et al., 2002), such as
IKK–NF-κB, p38 (Deng et al., 2008), and JNK (Wu and Cederbaum, 2008), are likely
critical components of hepatocellular toxicity responses to idiosyncratic drug-inflammatory
cytokine co-exposure.
Idiosyncratic hepatotoxicants are hypothesized to induce a diversity of sub-lethal injuries
that sensitize hepatocytes to inflammatory cytokine-induced cell death (Kaplowitz, 2005).
This hypothesis is supported by the demonstration that acetaminophen (APAP), at high
doses, can elicit an idiosyncratic-like hepatotoxicity that is dependent on cytokine signaling
as part of the innate immune response (Kaplowitz, 2005). At high doses, accumulation of a
cytochrome P450-dependent APAP metabolite leads to depletion of GSH in hepatocytes,
which is known to sensitize hepatocytes to TNF-induced apoptosis (Mari et al., 2008). In
limiting our analysis to hepatotoxicants that induced only a single type of sub-lethal injury,
we found clear correlations between injury mechanism and hepatotoxicity effects by
different cytokine treatment variables via factorial analysis. In human hepatocytes,
telithromycin and trovafloxacin both induced only one type of sub-lethal injury,
mitochondrial membrane potential depletion (Figures 3C and S16) and elicited markedly
similar patterns of cytokine synergy as assayed by caspase 3/7 activity and represented
through factorial analysis that were not shared by other drug treatments (Figure S16). This
unique and specific relationship between drug-induced injury and drug-cytokine synergy
suggests that drug-induced mitochondrial injury may sensitize hepatocytes to apoptosis
induced by LPS and IL-1α, as has been similarly hypothesized for alcoholic hepatitis-
induced mitochondrial injury in hepatocytes (Hoek and Pastorino, 2002), but not TNF.
Alternatively, idiosyncratic drug hepatotoxicity could arise when idiosyncratic
hepatotoxicant-induced stresses amplify the hepatotoxic effects of pre-existing inflammatory
cytokine signaling. Our findings do not distinguish between these hypothesized
mechanisms. Instead they simply demonstrate that co-exposure of idiosyncratic
hepatotoxicants and inflammatory cytokines frequently leads to the synergistic amplification
of mild hepatotoxicities caused by each. Further investigation is necessary to clarify the
mechanisms of inflammation-associated idiosyncratic drug hepatotoxicity both generally
and for specific drugs.
The cytokine mix-specific responses evident in the hepatotoxicity data compendium
collected here (Figures 2 and S11) suggest that inflammation-associated idiosyncratic drug
hepatotoxicities might be avoided by limiting drug treatments to patients that do not have
plasma cytokine signatures (due to pre-existing inflammatory episodes, for example)
corresponding to known synergizing inflammatory environments. Further investigation of
drug-cytokine mix synergies over across greater number of drug compounds and cytokine
environments, beyond those associated with LPS-induced inflammation, would have to be
conducted to more thoroughly capture the diversity of patient-specific drug-cytokine
interactions in humans. This suggestion of “personalized” or “stratified” drug treatment
(Trusheim et al., 2007) to avoid toxicity would likely be necessitated only for drugs for
which comparably efficacious compounds are not available and could be combined with
pharmaco-metabolonomic phenotyping approaches (Clayton et al., 2006) to avoid both
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inflammation- and metabolism-associated idiosyncratic hepatotoxicities in a patient-specific
manner.
In a 90-drug screen in human hepatocytes, ~20% of idiosyncratic hepatotoxicants (those
compounds associated with DILI category P2; see Table S1) elicited hepatocellular death
synergy with a cytokine mix compared to only 3% of non-hepatotoxic drugs when using
each drug’s 100*Cmax concentration as a physiological dosing limit (Figure 4). Using a
generalized physiological dosing limit of 30 μM (based on 33-fold the median Cmax
concentration across all drugs in the study), ~15% of idiosyncratic hepatotoxicants and none
of non-hepatotoxic drugs elicited synergy. This demonstrates that, given drug
pharmacokinetic parameters to define a physiologically relevant dosing window (ideally
individually defined for each drug), in vitro drug-cytokine hepatocellular death synergy can
be utilized as a much-needed preclinicaltool for identifying potential inflammation-
associated idiosyncratic hepatotoxicants with reasonable throughput. As conducted here,
identification of inflammation-associated idiosyncratic drug hepatotoxicity based on in vitro
hepatocellular models depends on human pharmacokinetic data and would be most
reasonably used within an iterative preclinical-clinical toxicity assessment paradigm.
Furthermore, this work demonstrates the utility of a physiologically relevant drug dosing
limit of 100*Cmax to obtain a low false-positive rate, as many non-hepatotoxic drugs
synergistically induced human hepatocyte death at concentrations exceeding 100*Cmax (see
Table 1).
At least for a subset of six drugs, this study demonstrates that, in addition to human
hepatocytes, both rat hepatocytes and HepG2 cells can be useful hepatocellular systems for
reproducing inflammation-associated idiosyncratic drug hepatotoxicities. This unexpected
success in using hepatocellular systems more amenable to high-throughput screening
suggests that cytokine mix synergy screens may be implemented for preclinical drug
evaluation, but the utility of these cell systems may be limited to drugs whose toxicity is not
dependent on in vivo-like metabolite formation. Moreover, we demonstrate an information
theoretic approach that can identify particularly informative subsets of cytokine treatments
in rat hepatocytes and HepG2 that are not only equivalently informative of larger data sets in
human hepatocytes, but also are highly effective at training PLS regression models to
predict drug- and cytokine mix-induced hepatotoxicities across these cell systems (Figures 5
and 6). The utility of rat hepatocytes and HepG2 cells for screening inflammation-associated
idiosyncratic drug hepatotoxicity will need to be evaluated for a greater diversity drug
compounds to generate more confidence in their accuracy.
This work suggests numerous improvements in the further development of high-throughput
cell culture models used to predict inflammation-associated idiosyncratic drug
hepatotoxicity. In the large-scale screen conducted here (Figure 4), the limited number of
cytokine synergies with idiosyncratic hepatotoxicants (8 of 43 = 19%) was likely due to the
use of only one cytokine environment and one hepatocyte cell system and the fact that not
all DILI P2 drugs have idiosyncratic hepatotoxicities associated with inflammation.
Increases in identification accuracy could be obtained using a multi-variate predictive model
(Xu et al., 2008) calibrated from expanded measurements of drug-cytokine synergies at
multiple doses (up to the 100*Cmax limit) across multiple hepatocyte cell systems, additional
cytokine environments, and/or toxicity assays, which all were limited in the 90-drug screen
here. Additionally, hepatocyte cell culture models, such as three-dimensional microreactor
cultures using primary rat hepatocytes, that better maintain hepatic drug metabolism and
biliary transport characteristics over a chronic time-scale (more than 7 days) and are scalable
to medium-throughput screening demands (Domansky et al., 2005; Sivaraman et al., 2005;
Hwa et al., 2007) could be utilized to develop more physiologically relevant models of
inflammation-associated idiosyncratic drug hepatotoxicity. These systems could better
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capture the mix of chronic and acute hepatocyte responses to drugs and inflammatory
cytokines (Ganey et al., 2004) and, moreover, could be used to recapitulate the cyclic
changes in both drug and cytokine levels in a well-controlled manner, which were not
examined in this study.
Nonetheless, the work presented here validates the use of synergistic induction of
hepatocellular death by idiosyncratic hepatotoxicants and an inflammatory cytokine
environment as a much-needed in vitro tool for assessing inflammation-associated
idiosyncratic drug hepatotoxicity and provides a framework for further development of such
in vitro models to capture a greater complexity of and to elucidate the mechanistic basis of
inflammation-associated idiosyncratic drug hepatotoxicity.
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Figure 1.
Identification of drug dose-dependent hepatotoxicity synergies between a cytokine mix and
multiple idiosyncratic hepatotoxic drugs in primary rat hepatocytes (panels A-E) and HepG2
cells (panels F-J). Primary rat hepatocytes and HepG2 cells were cultured, treated, and
assayed for LDH (at 24 or 48 hours post-treatment) as described in Methods. Drugs were
dosed at varying concentrations in the presence or absence of a cytokine mix containing 100
ng/ml TNF, 100 ng/ml IFNγ, 20 ng/ml IL-1α, and 10 μg/ml LPS. LDH release values were
fold-change normalized to DMSO/no cytokine control samples from the same cell system.
(Note that LDH release axes are separately scaled for each plot.) Drugs from similar
chemical class and/or molecular target are plotted together, with the less or non-hepatotoxic
“comparison” drug in blue and the more idiosyncratic hepatotoxic drug in red. Data are
presented as mean ± SEM of four biological samples. Results from additional time points,
with drug doses plotted with respect to both molecular concentrations and drug Cmax values,
are shown in Figures S1–S5.
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Figure 2.
A drug- and cytokine mix-induced hepatotoxicity data compendium. Primary rat hepatocytes
(far left), primary human hepatocytes (left center), and HepG2 cells (right center) were
cultured, treated, and assayed for caspase 3/7 activity (top) or LDH release (bottom) at 24 or
48 hours post-treatment as described in Methods. In rat hepatocytes, the DMSO control and
ranitidine treatment conditions at t = 48 hr are shown in expanded bar plots for both assay
types (far right). Bar plot graphs for all combinations of cell type, assay type, and treatment
condition are shown in Figures S7-S9. Caspase 3/7 activity and LDH release values were
both fold-change normalized to DMSO/no cytokine samples from the same cell system. In
the heatmaps, mean toxicity assay values of three to six biological samples are plotted using
linear color-scales indexed separately to the minimum and maximum observed value for
each combination of cell system and assay type. In the bar plots, data are plotted as mean ±
SEM of four biological samples, with all conditions demonstrating statistically significant
supra-additive drug-cytokine mix synergy labeled (*) (see Methods). The cytokine mix
(TNF, IFNγ, IL-1α, and LPS) used in Figures 1 and S1-S5 is noted as “Mix”. Abbreviations:
Cla, clarithromycin; Tel, telithromycin; Nef, nefazodone; Tro, trovafloxacin; Nim,
nimesulide; Ran, ranitidine.
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Figure 3.
Hierarchical clustering of the drug-cytokine mix hepatotoxicity compendium. (A) The drug-
cytokine mix combinatorial hepatotoxicity compendium was fused across all cell systems
and assay types into a single data matrix, which was then subjected to two-way Pearson
clustering (top left; see Methods for additional details). First, clustering was used to re-sort a
matrix of 192 “experimental” conditions, comprised of combinations of three cell systems,
two assay types, and five cytokine treatment variables (top right). Second, this clustering
was used re-sort to a sub-lethal hepatotoxicity data matrix of eight drug conditions and four
drug (only)-induced sub-lethal hepatotoxicities (bottom). The sub-lethal hepatotoxicities
(measured by quantitative imaging in primary human hepatocytes; see Figure S16) are
plotted in the bottom heatmap using linear color-scales indexed separately to the minimum
and maximum observed toxicity value for each assay type. (Note that the MtMP and GSH
assay scales are inverted compared to Figures S16K-L.) Conditions used for the large-scale
primary human hepatocyte toxicity study (see Figure 4) are noted: (1) no cytokines and (2)
TNF, IL-1α, IL-6, and LPS. (B) Factorial effects ± errors of all one- and two-cytokine
effects from the caspase 3/7 activity data at t = 24 hr in primary human hepatocytes for
DMSO control, telithromycin, and trovafloxacin drug treatments. Statistically significant
factorial effects (see Methods and Figure S12) are labeled (*). (C) Sub-lethal
hepatotoxicities measured in primary human hepatocytes treated with DMSO control,
telithromycin, or trovafloxacin are plotted on a normalized scale as in panel (A). Data are
presented as mean ± SEM of five biological samples. For each assay type, treatments
significantly different from the DMSO control are labeled as significant (*) if P < 0.05 by a
Student’s t test. Abbreviations: RH, primary rat hepatocytes; HH, primary human
hepatocytes; G2, HepG2 cells; Cla, clarithromycin; Tel, telithromycin; Nef, nefazodone;
Tro, trovafloxacin; Nim, nimesulide; Ran, ranitidine; ROS, reactive oxygen species; MtMP,
mitochondrial membrane potential; GSH, glutathione.
Cosgrove et al. Page 23
Toxicol Appl Pharmacol. Author manuscript; available in PMC 2011 June 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
Large-scale drug-cytokine mix hepatotoxicity study in primary human hepatocytes
demonstrates the utility of cytokine co-treatment approach for identifying idiosyncratic
hepatotoxic drugs. Primary human hepatocytes were cultured, treated, and assayed for LDH
release (at 24 hours post-treatment) as described in Methods. Ninety drugs (see Table S3)
were each dosed at seven non-zero concentrations (2.5× serial dilutions from a high
concentration of 150 μM) in the presence or absence of a cytokine mix containing TNF,
IL-1α, IL-6, and LPS. The differential between + and - cytokine mix co-treatment for each
drug dose was calculated and is plotted in the heatmaps (see Figure S17 for raw data and
additional details). The heatmaps are split into hepatotoxic (DILI classes P1, O1, and P2;
left) and not or minimally hepatotoxic (DILI classes O2, N3, N2, and N1; right) drug
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groups, with these DILI classes sorted in order of decreasing hepatotoxicity (see Tables 1
and S1 for additional details). Note that DILI class P2 is substantially comprised of drugs
with idiosyncratic hepatotoxicities in humans. Within each DILI class, drugs are sorted in
order of 100*Cmax value (a physiologically relevant dosing limit). Drug 100*Cmax values
are plotted in an overlayed line plot, with values exceeding 150 μM not shown. Individual
drug doses that exhibited supra-additive drug-cytokine mix synergy (see Methods and Table
1) at concentrations less than their drug’s 100*Cmax limit are highlighted with gray boxes.
Drugs with one or more dose exhibiting drug-cytokine mix supra-additive toxicity synergy
at less than their 100*Cmax concentration are listed in red font. A representative DILI P2
drug (chlorpromazine) displaying drug-cytokine mix synergy at dosing concentrations less
than 100*Cmax is shown in the expanded plot at the bottom right (data presented mean ±
SEM of two biological samples). TPCA-1, a small molecule IKK inhibitor (IKKi), was used
(at ten-fold lower concentrations than are noted by the axis labels for the other drugs) as a
positive control for drug-cytokine mix synergy, but is not labeled in red as its Cmax is
unknown.
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Figure 5.
Representative subset identification using joint entropy analysis. In panel A, subsets of
cytokine co-treatments that maximally maintained the diversity of the full experimental
human hepatocyte (HH) data set were identified by exhaustively scoring all possible subsets
that contained the no cytokine and single-cytokine/LPS treatment conditions. The treatments
contained in the highest scoring set of each size are indicated by the white boxes. Red bars
represent the joint entropy of the maximally informative set. After 16–19 co-treatments are
selected, additional co-treatments do not increase the joint entropy, indicating that the
diversity of the full data set can be captured with a well-chosen set of 16–19 co-treatments.
See Figure S18 for maximum entropy subset plots for the rat hepatocyte (RH) and HepG2
(G2) data sets. In panel B, maximally informative consensus subsets were chosen using only
RH data, only G2 data, both RH and G2 data, or only HH data. The mean performance of
the top 100 subsets chosen from each cell system when scored for joint entropy in the HH
data is plotted, along with the mean and standard deviation joint entropy for all possible
subsets for the HH data. Sets chosen based on RH and G2 data still perform well when
scored against the HH data. In panel C, a single consensus set of each size was chosen from
each cell system and the scored for joint entropy in the HH data. The probability of
randomly choosing a subset with higher joint entropy is plotted as a function of set size.
Low values indicate that it is unlikely to randomly select a set with higher information
content than the evaluated set. The dashed line represents the average of all possible subsets.
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Figure 6.
Predictive performance of partial least-squares (PLS) models trained on consensus
maximum entropy sets and evaluated across cell systems. PLS regression models were built
using specific cytokine condition sets containing 25 of the 32 possible cytokine treatments,
selected based on data from rat hepatocytes (RH) and HepG2 cells (G2). They were
evaluated for their ability to predict responses of the 7 remaining cytokine treatment
conditions observed in human hepatocytes (HH). Pearson correlations (R) between the
observed and predicted responses in HH of both the caspase 3/7 activity (panel A) and LDH
release (panel B) responses are shown. Cytokine condition sets selected from RH and G2
data were chosen using either the consensus maximum entropy treatment sets or random
treatment sets, of which the mean performance of 1000 random treatment sets is plotted, and
these conditions sets were selected and evaluated using data from either all six drugs or
single drugs. Abbreviations: Cla, clarithromycin; Tel, telithromycin; Nef, nefazodone; Tro,
trovafloxacin; Nim, nimesulide; Ran, ranitidine.
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e 
ca
lc
ul
at
ed
 su
pr
a-
ad
di
tiv
e 
sy
ne
rg
y 
th
re
sh
ol
d 
w
er
e 
ch
ar
ac
te
riz
ed
 a
s s
yn
er
gi
st
ic
. T
hi
s “
ru
le
-o
f-
th
um
b”
th
re
sh
ol
d 
w
as
 u
se
d 
in
st
ea
d 
of
 a
 su
pr
a-
ad
di
tiv
e 
St
ud
en
t’s
 t 
te
st
 (s
ee
 M
et
ho
ds
 a
nd
 F
ig
ur
e 
S6
) a
s t
w
o 
or
 th
re
e 
bi
ol
og
ic
al
 sa
m
pl
es
 p
er
 c
on
di
tio
n 
w
er
e 
us
ed
 d
ue
 to
 th
e 
sc
re
en
in
g 
na
tu
re
 o
f t
hi
s l
ar
ge
-s
ca
le
 st
ud
y,
th
us
 li
m
iti
ng
 th
e 
ab
ili
ty
 to
 sa
tis
fy
 st
at
is
tic
al
 si
gn
ifi
ca
nc
e 
te
st
s. 
D
ru
g-
cy
to
ki
ne
 sy
ne
rg
y 
w
as
 a
ss
es
se
d 
w
ith
 re
ga
rd
s t
o 
tw
o 
di
ff
er
en
t m
et
ho
ds
 o
f d
ef
in
in
g 
a 
ph
ys
io
lo
gi
ca
lly
 re
le
va
nt
 d
os
in
g 
lim
it:
 (i
) u
si
ng
 e
ac
h
dr
ug
’s
 o
w
n 
33
*C
m
ax
 o
r 1
00
*C
m
ax
 c
on
ce
nt
ra
tio
n,
 o
r (
ii)
 u
si
ng
 th
e 
m
ed
ia
n 
33
*C
m
ax
 (3
0 
μM
) o
r 1
00
*C
m
ax
 (9
1 
μM
) c
on
ce
nt
ra
tio
n 
fo
r a
ll 
dr
ug
s i
n 
th
is
 st
ud
y 
(a
s a
n 
ge
ne
ra
l e
st
im
at
e 
of
 p
hy
si
ol
og
ic
al
ex
po
su
re
 li
m
it)
. I
f a
 d
ru
g 
de
m
on
st
ra
te
d 
cy
to
ki
ne
 sy
ne
rg
y 
at
 o
ne
 o
r m
or
e 
do
si
ng
 c
on
ce
nt
ra
tio
n 
w
ith
in
 th
e 
ph
ys
io
lo
gi
ca
l d
os
in
g 
lim
it 
ap
pl
ie
d,
 it
 w
as
 in
cl
ud
ed
 in
 th
e 
ag
gr
eg
at
e 
fo
r i
ts
 h
ep
at
ot
ox
ic
ty
 c
la
ss
. S
ee
Fi
gu
re
 5
 fo
r a
 li
st
 (t
ho
se
 d
ru
gs
 in
 re
d 
fo
nt
) o
f t
he
 d
ru
gs
 th
at
 sa
tis
fie
d 
sy
ne
rg
y 
co
nd
iti
on
 u
si
ng
 e
ac
h 
dr
ug
’s
 1
00
*C
m
ax
 c
on
ce
nt
ra
tio
n 
lim
it.
3 T
he
 st
at
is
tic
al
 si
gn
ifi
ca
nc
e 
of
 th
e 
ob
se
rv
ed
 n
um
be
r o
f s
yn
er
gi
st
ic
 d
ru
gs
 in
 th
e 
id
io
sy
nc
ra
tic
 h
ep
at
ot
ox
ic
 c
la
ss
 w
as
 a
ss
es
se
d 
us
in
g 
a 
hy
pe
rg
eo
m
et
ric
 te
st
 w
ith
 a
 n
ul
l h
yp
ot
he
si
s t
ha
t s
yn
er
gi
st
ic
 d
ru
gs
 w
ou
ld
no
t p
re
fe
re
nt
ia
lly
 p
op
ul
at
e 
ei
th
er
 o
f t
he
 h
ep
at
ot
ox
ic
ity
 g
ro
up
in
gs
.
Toxicol Appl Pharmacol. Author manuscript; available in PMC 2011 June 6.
